表紙:ヒトミルクオリゴ糖 (HMO) の世界市場:2021~2028年
市場調査レポート
商品コード
991630

ヒトミルクオリゴ糖 (HMO) の世界市場:2021~2028年

Global Human Milk Oligosaccharides Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
ヒトミルクオリゴ糖 (HMO) の世界市場:2021~2028年
出版日: 2021年07月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ヒトミルクオリゴ糖(HMO)は、母乳に存在する複雑な生理活性糖分子です。それは特定の有益なバクテリアの成長基質として機能します。構造的に多様で複雑であるため、製剤で使用するためにそれらを合成または抽出することは困難です。ヒトミルクオリゴ糖(HMO)は免疫にとって有益であるため、牛乳からHMOを分離する、高価な技術を実行する(化学的または酵素的に合成する)、微生物を利用してそれらを作成するなど、いくつかの新しい技術が主要企業によって開発されています。ヒトミルクオリゴ糖(HMO)製品は、少量のHMOを獲得するために大量の母乳を合成する必要があるため、コストがかかります。したがって、解決策として、合成および抽出技術が向上しています。

市場の成長を後押しする主な要因には、機能性飲料と乳児用調製粉乳の適用範囲の拡大、製品ラインの急速な技術進歩、健康に対する意識の高まりと乳業の増加が含まれます。

当レポートでは、世界のヒトミルクオリゴ糖 (HMO) 市場について調査分析し、市場の概要、市場成長への影響要因、各セグメント・地域別による市場規模と前年比成長、および主要企業などについて分析しています。

目次

第1章 世界のヒトミルクオリゴ糖 (HMO) 市場:調査範囲・手法

  • 調査手法
  • 調査目的・範囲

第2章 世界のヒトミルクオリゴ糖 (HMO) 市場:市場の定義・概要

第3章 世界のヒトミルクオリゴ糖 (HMO) 市場:エグゼクティブサマリー

  • 市場内訳:アプリケーション別
  • 市場内訳:地域別

第4章 世界のヒトミルクオリゴ糖 (HMO) 市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 影響分析

第5章 世界のヒトミルクオリゴ糖 (HMO) 市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 世界のヒトミルクオリゴ糖 (HMO) 市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以降または将来のシナリオ
  • Covid-19期間中の価格ダイナミクス
  • 需要と供給のスペクトル
  • パンデミック期間中の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界のヒトミルクオリゴ糖 (HMO) 市場:アプリケーション別

  • イントロダクション
  • 市場規模分析および前年比成長分析(%):アプリケーション別
  • 市場魅力指数:アプリケーション別
    • 乳児用調製粉乳
    • 機能性食品および飲料
    • 栄養補助食品

第8章 世界のヒトミルクオリゴ糖 (HMO) 市場:地域別

  • イントロダクション
    • 市場規模分析および前年比成長分析(%):地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析および前年比成長分析(%):アプリケーション別
    • 市場規模分析および前年比成長分析(%):エンドユーズ別
    • 市場規模分析および前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第9章 世界のヒトミルクオリゴ糖 (HMO) 市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第10章 企業プロファイル

  • BASF SE
    • 企業概要
    • 製品ポートフォリオ・説明
    • 主なハイライト
    • 財務概要
  • Inbiose NV
  • Elicityl S.A.
  • Jennewein Biotechnologie GmbH
  • Glycom A/S
  • Medolac Laboratories
  • ZuChem Inc
  • Glycosyn LL
  • Shanghai Biochemical Co., Ltd.
  • Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
  • Beijing Solarbio Science & Technology Co., Ltd.
  • Anhui Elite Industrial Co., Ltd.,

第11章 世界のヒトミルクオリゴ糖 (HMO) 市場:重要考察

第12章 世界のヒトミルクオリゴ糖 (HMO) 市場:DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMFB3101

Market Overview

Human milk oligosaccharides (HMO) are present in human milk in the form of a complex bioactive sugar molecule. HMOs are growth substrates for certain useful bacteria. Extracting or synthesizing HMO in the formula is quite difficult as they are structurally diverse and complex. The human milk oligosaccharides (HMO) products available in the market are quite expensive as a huge quantity of human milk is synthesized just to obtain a small amount of HMO. Increasing concerns among consumers regarding gut health and the growing consumption of dietary supplements are expected to drive the growth. The global human milk oligosaccharides market valued USD XX million in 2020 and is forecasted to reach USD XX million by 2028, growing at a CAGR of XX% during the forecast period (2021-2028)

Market Dynamics

Increasing demand for infant nutrition products

In the recent past, infant formula ingredients such as human milk oligosaccharides have become popular as an ingredient in the infant formula to meet the demands of the baby nutrition segment. Health benefits associated with the consumption of human milk oligosaccharides include maintaining gut microbiota and inhibition of pathogen in infants. China accounts for 30% of the global consumption of Infant formula which is followed by other Asian countries holding 28% of the market. About 65% of the growth in Infant formula market comes from China. In the United States, the HMO's intended for use in food other than dietary supplements are regulated under GRAS. In U.S CARE4U™ by DuPont was approved as GRAS, for use in infant formula and toddler foods. With the increasing demand for HMOs, in 2018, two HMO's have gone through the novel food safety assessment in Europe, with a positive assessment outcome and approval by the European Commission. In addition, due to the prebiotic functions and the antimicrobial protection of HMOs, they are increasingly used as a useful ingredient in products such as medicinal food, pharmaceutical, and infant formulas, thus driving the growth of the human milk oligosaccharides (HMO) market.

However, high cost associated with HMO products is expected to act as a restraint for the market growth. For example, expensive substrates such as glycosyl transferases require enzyme synthesis and this is one of the main factors attributable to the high pricing of human milk oligosaccharides. Prebiotics in infant formula, such as fructooligosaccharides and galactooligosaccharides, are used to inhibit the development of pathogenic Escherichia coli. Consumption of these has been shown to improve the health of infants' gastrointestinal tracts by promoting the development of specific microorganisms in the intestinal microflora. Owing to their low cost and wide availability, these are being used as a replacement for human milk oligosaccharides by infant formula manufacturers. As a result, these functionally equivalent alternatives to human milk oligosaccharides are severely limiting the overall market's expansion.

Market Segmentation

3'-Fucosyllactose (3'FL) is expected to dominate the global human milk oligosaccharides (HMO) market by product segment

3' FL plays an important role in the development of gut microbiota in both adults and infants. The Nestle Nutrition Institute, in a study, stated that HMO concentrations change during different stages of lactation with different types showing different dynamics. Products such as 6'SL or LNT decrease more rapidly within the first weeks of lactation, although, for example, 2'FL and 3'SL decrease more slowly over a longer period of time and again others, such as 3FL, actually increase concentration with time of lactation. In November 2019, DuPont Nutrition & Biosciences applied for a patent for the use of 3'-FL as a novel food.

2'-Fucosyllactose is poised to grow with the fastest CAGR of XX% in the forecast period 2021-2028 as dietary supplement manufacturers shift to 2'-Fucosyllactose, since it is capable of altering gut microbiota composition and behavior from formula-powered infants receiving additional feeding, and its contribution to healthy digestion.

Geographical Penetration

North America is the largest market for human milk oligosaccharides with a share of nearly XX% in global sales value in 2020

By geography, North America is expected to dominate the human milk oligosaccharides (HMO) market. North America has registered increased demand for donor human milk. On the other hand, there exist only 11 milk banks in countries such as Canada and the U.S., which is actually not sufficient to meet the increasing demand for donor milk. This factor will increase the usage of HMO in the infant formula in order to provide proper nutrition to the babies.

Asia Pacific is expected to grow with a CAGR of XX% during the forecast period. According to the WHO, in the next 10 years, the overall world population is expected to rise by about one billion and reach 9.5 billion by 2050. The constantly growing population is likely to increase demand for infant nutrition products in the Asia Pacific especially in countries like China and India owing to the high infant population. Moreover, rising concerns regarding gut diseases, high blood pressure, diabetes, and rickets among other chronic diseases have resulted in an increased demand for functional food and beverages, which is expected to propel the regional demand for human milk oligosaccharides.

Competitive Landscape:

The global human milk oligosaccharides (HMO) market is fragmented. The most active companies across the globe are BASF Corporation, DuPont Nutrition, and Health, ZuChem Inc. and Jennewein Biotechnologie GmbH among others. They have been expanding their geographical presence by acquiring or merging with the manufacturers in the foreign market. For instance, in February 2019, Jennewein Biotechnologie GmbH, a Germany-based functional sugars manufacturer, partnered with Yili.Com Inc., a China-based dairy products manufacturer, to research on infant microbiome and human milk oligosaccharides. This strategy was intended to develop innovative, HMO-based infant formula and was targeted at customers in China. Such developments/strategies are likely to surface over the forecast period, given the rising competition in the market. In May 2019, Glycosyn LLC and BASF SE signed an agreement for the development and commercialization of HMOs for widespread use in dietary supplements, functional nutrition, and medical food. As part of the collaboration and under the exclusive license, BASF SE will extend its offering of the most abundant HMO, 2'-Fucosyllactose (2'-FL) branded PREBILACTM, to emerging markets.

COVID-19 Impact: The market witnessed a positive impact owing to increasing demand for dietary supplements

A robust and diverse food supply is an essential part of the health and nutrition response to COVID-19. The demand for nutraceuticals & functional foods is expected to witness an upward surge owing to consumers opting for immunity boosting supplements during the COVID-19 pandemic. The use of HMOs in dietary supplements offer benefits such as immune support, protection against bacterial and viral infections, digestive comfort, and brain function support. Furthermore, a decline in the consumption of poultry, meat and seafood products across the globe is expected to increase the demand for plant and animal-based protein supplements in the near future.

Why Purchase the Report?

  • Understand the current market scenario and viability of global human milk oligosaccharides over the forecast period.
  • Visualize the composition of the global human milk oligosaccharides market in terms of product, type, and application to identify major players, growth potential, and market strategies
  • Identify the key regulations prevailing in the market and understand their impact on the market over the forecast period
  • Understand the key business factors such as market competition, product pricing, new product developments, and patent filings pertaining in the market

What we offer?

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Excel data sheet with valuable data points of the global human milk oligosaccharides market - Regional and Country level segmentation
  • Product mapping in excel for the key products of all major market players
  • Market Share Analysis covering business revenues ($) and revenue share (%) of key market players

Target Audience:

  • Human Milk Oligosaccharides (HMO) Manufacturers
  • Infant Formula Products Manufacturers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals

Table of Contents

1. Global Human Milk Oligosaccharides Market -Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Global Human Milk Oligosaccharides Market -Key Trends and Developments

3. Global Human Milk Oligosaccharides Market - Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Type
  • 3.3. Market Snippet by Application

4. Global Human Milk Oligosaccharides Market - Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing demand for infant nutrition products
      • 4.1.1.2. The surge in the number of working mothers
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with products
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Global Human Milk Oligosaccharides Market - Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. Global Human Milk Oligosaccharides Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. Global Human Milk Oligosaccharides Market - By Product

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product segment
    • 7.1.2. Market attractiveness index, By Product segment
  • 7.2. Lacto-N-neotetraose (LNnT)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 And Y-O-Y Growth Analysis (%), 2020-2028
  • 7.3. Lacto-N-tetraose (LNT)
  • 7.4. 2'-Fucosyllactose (2'FL)
  • 7.5. 3'-Fucosyllactose (3'FL)
  • 7.6. 3'-Sialyllactose (3'SL)
  • 7.7. 6'-Sialyllactose (6'SL)
  • 7.8. Others

8. Global Human Milk Oligosaccharides Market - By Type

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Type segment
    • 8.1.2. Market attractiveness index, By Type segment
  • 8.2. Neutral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 And Y-O-Y Growth Analysis (%), 2020-2028
  • 8.3. Acidic
  • 8.4. Others

9. Global Human Milk Oligosaccharides Market - By Application

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
    • 9.1.2. Market attractiveness index, By Application Segment
  • 9.2. Infant Formula*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 And Y-O-Y Growth Analysis (%), 2020-2028
  • 9.3. Dietary Supplements
  • 9.4. Functional Food and Beverages
  • 9.5. Others

10. Global Human Milk Oligosaccharides Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America*
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 10.5.7.
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country

11. Global Human Milk Oligosaccharides Market - Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Elicityl SA
    • 12.1.1. Company Overview
    • 12.1.2. Type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Medolac Laboratories
  • 12.3. Inbiose NV
  • 12.4. Glycosyn
  • 12.5. ZuChem
  • 12.6. Jennewein Biotechnologie Gmbh
  • 12.7. Glycom A/S
  • 12.8. Dextra Laboratories Limited
  • 12.9. DuPont Nutrition & Health
  • 12.10. Nestle Health Science
  • List not Exhaustive*

13. Global Human Milk Oligosaccharides Market - Premium Insights

14. Global Human Milk Oligosaccharides Market - DataM

  • 14.1. Appendix
  • 14.2. About us and services
  • 14.3. Contact us